Showing results (81-90 of 396) with videos related to
Sort By:
Pageof 40
The Journal of Investigative Dermatology|August 25, 2015
BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic EscapeInna V Fedorenko, Jennifer A Wargo, Keith T Flaherty, et al.Molecular Cancer Therapeutics|May 30, 2006
Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastasesKeiran S M Smalley, Nikolas K Haass, Patricia A Brafford, et al.Cancer Chemotherapy and Pharmacology|February 26, 2011
Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction studyKeith T Flaherty, Chetan Lathia, Reginald F Frye, et al.Plos One|April 12, 2011
A melanoma molecular disease modelSmruti J Vidwans, Keith T Flaherty, David E Fisher, et al.Nature Reviews. Drug Discovery|April 2, 2010
LiraglutideDaniel J Drucker, Argyris Dritselis, Peter KirkpatrickNature Reviews. Drug Discovery|October 1, 2011
Ezogabine (retigabine)Carl E Stafstrom, Seden Grippon, Peter KirkpatrickNature Reviews. Drug Discovery|June 2, 2010
Meningococcal group A, C, Y and W-135 conjugate vaccineLee H Harrison, Nitin Mohan, Peter KirkpatrickNature Reviews. Drug Discovery|March 31, 2012
AfliberceptMichael W Stewart, Seden Grippon, Peter KirkpatrickCancer Discovery|July 22, 2021
Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency PerspectiveKeith T Flaherty, James H Doroshow, Susan Galbraith, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2011
New challenges in endpoints for drug development in advanced melanomaAntoni Ribas, Peter Hersey, Mark R Middleton, et al.Pageof 40